DanCann Pharma A/S signs Letter of Intent with Aureum Pharma AB for exclusive rights with a minimum commitment of SEK 37 million
COPENHAGEN, Denmark, 12 May 2022 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the “Company”), a Danish company powered by cannabinoids, hereby announce that the Company has signed Letter of Intent with Aureum Pharma AB (“Aureum Pharma”) for exclusive rights over its products in Sweden.DanCann Pharma is a highly experienced manufacturer of medical cannabis products in Denmark. Aureum Pharma is an entity permitted per Swedish law to import and distribute medical cannabis products. DanCann Pharma and Aureum Pharma aims to enter into a binding supply and distribution agreement